Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery. The strategic rationale for the move centers on the high degree of alignment between the target’s fully integrated German manufacturing capabilities and the acquirer’s focus on high-moat, regulatory-intensive industrial platforms. By partnering with the founding family during a structured transition phase, the acquirer aims to professionalize the management framework and accelerate international market penetration. The partnership is designed to leverage the acquirer’s financial depth to drive targeted investments in product innovation and further certifications. This integration facilitates the scaling of the target’s proprietary brand while reinforcing its status as a mission-critical CDMO partner for global MedTech giants. This move solidifies the group’s standing as a primary enabler of technological modernization in the surgical instrument market.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.